Stock Code: 002083 Stock Abbreviation: Furui Group Co., Ltd. Independent Director 2025 Annual Report
Dear shareholders and representatives:
As an independent director of Furui Group Co., Ltd. (hereinafter referred to as "the Company"), I commenced my duties on July 16, 2025. During my tenure, I strictly adhered to the "Company Law of the People's Republic of China," "Measures for the Administration of Independent Directors of Listed Companies," and other relevant laws and regulations, as well as the "Articles of Association" and "Independent Director Work System" of the Company. I performed my duties independently, fairly, and diligently, actively attended relevant meetings, carefully reviewed various proposals, provided professional and objective opinions and suggestions for the Company's operational development, continuously improved the decision-making level of the board of directors, promoted decisions that align with the overall interests of the Company, and protected the legitimate rights and interests of investors. Below is my report on the performance of my duties in 2025:
I. Overview of Independent Director's Annual Performance
In 2025, I attended shareholder meetings, board meetings, and special committee meetings with a diligent and responsible attitude, carefully reviewing meeting documents and related materials. I exercised my voting rights cautiously based on my areas of expertise, faithfully fulfilling my responsibilities as an independent director.
(1) Attendance at Board and Shareholder Meetings
This year, I participated in 6 board meetings, was required to attend 3 shareholder meetings, and attended 3 additional meetings. I voted in favor of all proposals presented at the board meetings held during the year. As an independent director, I proactively sought to understand and obtain the necessary information and materials before making decisions, conducted on-site investigations of the Company, and kept abreast of the Company's production operations and business conditions to prepare adequately.
During my tenure, the proposals reviewed at the board and shareholder meetings did not harm shareholder interests. I listened carefully to and deliberated on each agenda item, actively participated in discussions, and provided reasonable suggestions, contributing positively to the scientific decision-making of the board.